A

AbbVie

Global biopharmaceutical company developing medicines

Junior Internal Communications Specialist

Full-Time
No salary listed
Junior
Bachelor's
Dubai - United Arab Emirates
Hybrid
Growth & MarketingPR & Communications

About the job

Requirements
  • A bachelor's degree in communications, journalism, public relations, marketing, or a related field.
  • One to two years of relevant experience, including internships, co-op placements, graduate roles, or entry-level experience.
  • Exposure to communications, content development, employee engagement, events, marketing, public relations, or a related area.
  • Good written and verbal communication skills in English and Arabic.
  • Foundational business writing, editing, proofreading, and presentation-development skills.
  • Good organizational and time-management skills, with the ability to track assignments and meet agreed deadlines.
  • Ability to manage multiple routine assignments and prioritize work with guidance.
  • Proficiency in Microsoft Office, particularly Word, PowerPoint, Outlook, virtual meeting platforms such as Microsoft Teams and Zoom, and basic Excel.
  • Ability to work independently and collaboratively in a team environment.
  • Process-oriented, adaptable, and able to work effectively in ambiguity.
  • Professional demeanor and ability to maintain confidentiality.
  • Interest in or exposure to healthcare, pharmaceutical, biopharmaceutical, or regulated industries.
Responsibilities
  • Support the preparation of internal communication activities under the direction of the Government Affairs & Communications Director.
  • Draft, edit, format, proofread, and distribute internal communications, including announcements, newsletters, presentations, talking points, intranet content, and campaign materials.
  • Support the development and distribution of communications related to business updates, company priorities, employee initiatives, and organizational activities.
  • Create social media content that aligns with corporate branding guidelines and strict industry regulations.
  • Assist with preparing communication materials for different employee audiences and internal stakeholders.
  • Support the preparation and maintenance of content for internal communication channels, including email, newsletters, intranet, collaboration tools, employee meetings, and town halls.
  • Assist with coordinating internal events, employee engagement activities, leadership meetings, business updates, and culture initiatives.
  • Support the scheduling and distribution of approved communication materials through appropriate internal channels.
  • Respond to routine communication requests from internal stakeholders.
  • Provide administrative and coordination support to the Communications function.
  • Coordinate routine follow-up with internal stakeholders under the direction of the Government Affairs & Communications Director.
  • Assist with the local adaptation and distribution of communication materials provided by regional or global Communications teams.
  • Collaborate with colleagues across functions to gather information and support communication activities.
  • Maintain effective working relationships with internal stakeholders and seek guidance when required.
  • Prepare communication materials in accordance with approved corporate branding guidelines, compliance requirements, and privacy rules.
  • Review materials for accuracy, clarity, consistency, formatting, and completeness.
  • Ensure required approvals are obtained before communications are distributed.
  • Maintain the confidentiality of sensitive information and follow applicable company policies and procedures.
  • Escalate complex, sensitive, potentially high-risk, or competing-priority matters to the Government Affairs & Communications Director.
  • Collect basic communication activity information, employee feedback, and results.
  • Support the preparation of communication activity updates and basic reports.
  • Maintain accurate records of communication activities, deliverables, and timelines.
  • Identify opportunities to improve the efficiency and effectiveness of communication activities.
Desired Qualifications
  • Familiarity with SharePoint, intranet, collaboration tools, newsletters, and other digital communication platforms.
  • Basic knowledge of corporate branding, visual communication, and content production.
  • Experience or coursework involving social media, digital content, design, or multimedia communication.
  • Basic knowledge of communication metrics, analytics, or employee feedback tools.
  • Familiarity with working in a regional or multinational organization.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.

Yahoo Finance
Oct 18th, 2026
Ken Griffin's Citadel boosts AbbVie stake 546% in Q2 as defensive dividend play

Citadel founder and chief executive officer Ken Griffin made healthcare his biggest bet in the second quarter. He bought 2.7 million AbbVie shares, a 546% increase from the previous quarter, and added 6.7 million shares of Abbott Laboratories, up 349%. He also raised his Eli Lilly stake by 291%, the third-biggest individual equity add. The moves suggest a defensive stance. Healthcare stocks tend to hold up in downturns, and both AbbVie and Abbott are Dividend Kings, having raised dividends for 54 straight years. AbbVie yields 2.65% and trades at 16 times forward earnings. In the second quarter, its adjusted earnings rose 23% and net revenue rose 10%. Some 75% of analysts covering the stock rate it a buy.

Yahoo Finance
Oct 17th, 2026
AbbVie's 54-year dividend streak and $7.5B quarterly drug sales make it a rate-proof income pick

AbbVie (NYSE: ABBV) looks well placed to keep paying dividends through any interest rate cycle, according to a Motley Fool analysis. The drugmaker has raised its dividend for 54 consecutive years, including its time as part of Abbott Laboratories, which makes it a Dividend King. It generates more than enough free cash flow to cover its quarterly dividend of $1.73 per share. Of its $70.8 billion in debt, much is fixed-rate, so rate moves matter less. Skyrizi and Rinvoq brought in over $7.5 billion in the second quarter of 2026, above the $6.1 billion paid in dividends. About 90 programs are in clinical development. The dividend yield is 2.5%, lower than in the past because the share price has climbed. Pipeline setbacks remain a risk.

MarketScreener
Oct 17th, 2026
AbbVie announces SKYRIZI and RINVOQ data highlighting long-term clinical and endoscopic outcomes across inflammatory bowel disease at UEGW 2026.

AbbVie announces SKYRIZI and RINVOQ data highlighting long-term clinical and endoscopic outcomes across inflammatory bowel disease at UEGW 2026. Published on 10/17/2026 at 04:35 am EDT S&P Capital IQ AbbVie (NYSE: ABBV) announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology (UEG) Week, October 17-20 in Barcelona, Spain. Together, the data reflect the breadth of AbbVie's research across IBD, including established therapies studied over longer treatment periods and in real-world clinical practice. Key data to be presented include long-term data in moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD)? Open-label extension and post-hoc analyses add to the evidence base for clinical and endoscopic outcomes with risankizumab and upadacitinib. Risankizumab in UC: COMMAND showed sustained clinical and endoscopic outcomes up to three years of maintenance treatment. As-observed clinical remission rates of 54.0%?73.1% and endoscopic remission rates of 38.8%?53.5% were achieved at week 96 with 180mg across advanced therapy-naïve and advanced therapy-experienced patients. Upadacitinib in CD: U-ENDURE as-observed analyses showed that clinical and endoscopic outcomes were maintained through approximately four years of treatment. At Week 144, clinical remission was achieved by 78.9% of patients receiving 15 mg and 86.6% receiving 30 mg. Endoscopic remission was achieved by 47.1% and 64.2% of patients, respectively. Interim results from the real-world UPlift study showed that 70.2% of evaluable patients (N=497) with moderate to severe Crohn's disease achieved clinical response with upadacitinib within 12 weeks, with a median time to first response of 13 days. A real-world claims analysis of patients (N=514) with UC or CD showed that patients who switched from a Tumor Necrosis Factor inhibitor (TNFi) to upadacitinib had lower rates of IBD-related hospitalizations (9.5% vs 16.3%) or surgery (6.9% vs 10.6%) over 12 months compared with patients who cycled to another TNFi. Data presented at UEGW will further expand on findings from the Phase 3 AFFIRM study evaluating subcutaneous risankizumab induction and maintenance in CD. Following the first presentation of AFFIRM results at the 2026 American College of Gastroenterology Annual Scientific Meeting, the UEGW presentations will provide additional analyses examining outcomes by prior advanced therapy exposure and further characterizing clinical and endoscopic outcomes among patients who responded to subcutaneous risankizumab induction and continued treatment. ABBV-466 is an investigational dual-targeting therapy combining risankizumab, an IL-23 inhibitor, with trosunilimab, an a4ß7 inhibitor, to address complementary drivers of inflammation in Crohn's disease. ABBV-466 is investigational and its safety and efficacy have not been established by regulatory authorities. (C) S&P Capital IQ - 2026